Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
Search
GLP-1/FGF21 agonist
GLP-1/FGF21 agonist
New indications NexGard, NexGard SPECTRA and Broadline
New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA
Banana Coconut Bread
Find out how to make this sweet, mouth-watering banana coconut bread recipe from Taking Cancer on Through Flavour and Taste Life.
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
KRAS multi-inhibitor
KRAS multi-inhibitor
NPY2r agonist
Food intake regulator
Women in STEM: Passion for science
Discover how our women excelling in STEM careers can improve health equity and create sustainable healthcare solutions.
Kicking off 2024 with five new R&D partnerships
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
Empowering Patients
Empowering Patients
Survodutide (BI 456906)
Survodutide (BI 456906)
BI 765845
Heart disease modulator
Pets
Pets
Patient advocacy tips for cancer
Colorectal Cancer
Colorectal Cancer Infographic
Lung Cancer Backgrounder.pdf
cancer_statistics_and_incidence_rates.pdf
Lung Cancer Backgrounder_0.pdf
Lung_Cancer_Backgrounder.pdf
Nerandomilast (BI 1015550)
Nerandomilast (BI 1015550): PDE4B inhibitor
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
Research Collaborations
Research Collaborations
Clinical Collaborations
Clinical Collaborations